Test detects prior infection by Zika virus

March 29, 2018, FAPESP
Set to come to market this year, the test identifies antibodies that remain in the organism for years after the acute phase and provide immunity. The method was developed thanks to FAPESP’s Innovative Research in Small Business Program . Credit: FAPESP

A test that detects antibodies against Zika virus in samples of blood serum with high specificity—and hence a low risk of cross-reaction with related microorganisms such as dengue virus—is set to enter the Brazilian market before 2018 is out.

The method was designed by Brazilian scientists. Technology firm Inovatech, with the support from the São Paulo Research Foundation—FAPESP through its Innovative Research in Small Business Program (PIPE), developed the test in collaboration with scientists at the University of São Paulo's Biomedical Science Institute (ICB-USP) and at the Butantan Institute.

"We're in the final stages of developing a serological test to detect immunoglobulin G (IgG) antibodies, which remain in the organism for many years after infection, providing lifelong immunity. We expect it to be approved for sale in the second half of this year," said Danielle Bruna Leal de Oliveira, a researcher at ICB-USP's Clinical & Molecular Virology Laboratory and principal investigator for the project.

Since the creation in 2016 of the Zika Virus Research Network in São Paulo (Rede Zika), which is supported by FAPESP, developing this type of diagnostic method has been considered a priority.

A tool of this kind, according to the scientists, is essential for answering several strategic questions for any plan of action against the disease: What is the exact size of the epidemic (distinguishing more precisely between cases of dengue and Zika, in both current and past outbreaks)? What proportion of pregnant women are infected (and hence immune)? How many women risk giving birth to babies with neurological problems due to congenital infection?

"The idea is to include this test in the prenatal examination process," Oliveira said. "If we can do that, with a negative result [meaning they have never been infected] will take more precautions, such as avoiding travel to high-risk areas and using insect repellent. Meanwhile, those who are immune will be able to stop worrying."

According to Oliveira, currently available diagnostic tests either work only in the acute phase of infection—as is the case with the molecular method (real-time PCR) and chromatography, which detect viral RNA in the bloodstream—or detect Zika antibodies with low specificity.

"The specificity of the serological tests currently on the market falls within the 69%-75% range. So there's at least a 25% chance of a false positive if the patient was infected by in the past. Our test's specificity is 93% for Zika," Oliveira said.

Like its predecessors, the test developed by Inovatech is based on a methodology known as ELISA, an acronym for enzyme-linked immunosorbent assay. The platform consists of a microtiter plate with 96 tiny wells to which adheres a recognized by the human immune system.

The wells are filled with from up to 94 patients, with two or more being reserved for controls. In the case of prior contact with Zika, IgG antibodies adhere to the viral protein, which is later detected by a colorimetric assay (positive and negative samples acquire different colorings).

"One of the difficulties associated with the method is that the viral protein commonly used, NS1, is very similar in all flaviviruses [the family Flaviridae includes dengue, Zika and yellow fever, among others]. To solve this problem, we used an edited version of the protein, selecting only the most Zika-specific part of the molecule," Oliveira explained. This "truncated" version of NS1 (δNS1) was developed by Luis Carlos de Souza Ferreira and his team at ICB-USP.

To reduce the risk of cross-reaction with dengue virus still further, Inovatech's researchers added another stage to the assay. Before the blood serum from patients is placed in the ELISA plate in contact with δNS1, it is exposed to proteins from dengue virus, with the aim of extracting all antibodies against this pathogen from the samples.

"The drawback is that it takes a little longer to get a result—about three hours, compared with two hours and twenty minutes for conventional ELISA—but we're working on a way to make it faster. The goal is that it should be quicker than the standard method because it's designed for use by hospitals in patient screening," Oliveira said.

Low cost

Selected in a call for proposals (in Portuguese) issued in 2016 under the aegis of an agreement between FAPESP and FINEP, the Brazilian Innovation Agency, the project coordinated by Oliveira aims to create a fast, low-cost serological test to detect both IgG and IgM (immunoglobulin M), which stays in the organism for up to about four months after the end of infection by Zika.

"We focused on IgG throughout 2017, and this year, we're focusing on the development of a methodology to detect IgM," Oliveira said.

Her group will be assisted by ICB-USP researchers Edison Luiz Durigon and Luiz Carlos Ferreira, as well as Butantan Institute researchers Roxane Piazza and Viviane Botosso.

Although the time taken to obtain a result must be further reduced, the low-cost part of the project's goal has been achieved. Oliveira estimates the cost of the assay to detect IgG at about BRL 10-12 per patient (now about USD 3.00-3.70).

Inovatech has also completed another important step toward bringing its product to market: it has won a Manufacturing Best Practice (BPF) certificate from ANVISA, the national health surveillance agency. The first batches for experimental use are already being produced.

Explore further: New test extends window for accurate detection of Zika

Related Stories

New test extends window for accurate detection of Zika

March 6, 2018
Diagnosis of Zika infection is complex. Molecular tests for exposure are only reliable in the first two to three weeks after infection while the virus is circulating in the bloodstream. Antibody tests are confounded by cross-reactivity ...

How reliable is diagnostic testing for Zika?

March 2, 2018
Globally, Brazil has been the hardest hit by the current Zika outbreak, and the country reports almost all cases of Zika-associated malformations in newborns. DZIF scientists from the Charité - Universitätsmedizin Berlin ...

New Zika serotypes may emerge, researcher warns

October 11, 2017
Zika virus is mutating so quickly in Brazilian patients that different serotypes of the pathogen could appear in the near future, as is already the case with dengue virus. This would hinder the production of a vaccine and ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

Laboratory technique can detect Zika virus infection and make diagnostic tests more accessible

December 22, 2017
A new test for the Zika virus could help limit future outbreaks, especially in areas without access to sophisticated diagnostic methods.

Pregnant women advised to be tested more than once for the presence of Zika

November 2, 2017
Molecular tests to identify Zika's genetic material in body fluids during the acute phase of infection have been used routinely in prenatal checkups for pregnant women with symptoms of the disease. Now, a new study conducted ...

Recommended for you

Study predicts 2018 flu vaccine will have 20 percent efficacy

April 19, 2018
A Rice University study predicts that this fall's flu vaccine—a new H3N2 formulation for the first time since 2015—will likely have the same reduced efficacy against the dominant circulating strain of influenza A as the ...

Zika presents hot spots in brains of chicken embryos

April 19, 2018
Zika prefers certain "hot spots" in the brains of chicken embryos, offering insight into how brain development is affected by the virus.

Low-cost anti-hookworm drug boosts female farmers' physical fitness

April 19, 2018
Impoverished female farm workers infected with intestinal parasites known as hookworms saw significant improvements in physical fitness when they were treated with a low-cost deworming drug. The benefits were seen even in ...

Super-superbug clones invade Gulf States

April 18, 2018
A new wave of highly antibiotic resistant superbugs has been found in the Middle East Gulf States, discovered by University of Queensland researchers.

Of mice and disease: Antibiotic-resistant bacteria discovered in NYC house mice

April 17, 2018
A study by scientists at the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health finds New York City house mice carry bacteria responsible for mild to life-threatening gastroenteritis ...

Discovery explains how the chickenpox and shingles virus remains dormant

April 16, 2018
A research team led by UCL and Erasmus University has found a missing piece to the puzzle of why the virus that causes chickenpox and shingles can remain dormant for decades in human cells.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.